Last checked: 20 November 2026, 5:09 a.m. UTC.
Australia’s Therapeutic Goods Administration (TGA) has registered Wegovy tablets, and the medicine is moving into private-prescription availability from 20 November. That is a change from the earlier expectation that the tablets would arrive before the end of the year. Registration clears the regulatory step, but it does not guarantee that every pharmacy has stock on hand; patients should check availability with a pharmacy and speak with a prescriber.
The TGA’s decision covers four strengths—1.5 mg, 4 mg, 9 mg and 25 mg—for eligible adults. The tablets contain semaglutide, the same active ingredient as injectable Wegovy. They are a prescription medicine, and the TGA approval does not itself mean the tablets are subsidised through the Pharmaceutical Benefits Scheme (PBS). The TGA’s decision summary records the tablet registration and approved uses.
Destaques
- The TGA registered Wegovy tablets in Australia on 3 November 2026.
- The approved tablet strengths are 1.5 mg, 4 mg, 9 mg and 25 mg.
- Private-prescription availability is reported to begin on 20 November, but pharmacy stock may vary.
- Registration does not automatically mean PBS subsidy or immediate stock at every pharmacy.
Is the Wegovy pill available in Australia now?
Yes, the tablet has been registered by the TGA, and Australian reporting says private prescriptions can begin from 20 November. Registration and commercial supply are separate steps: a medicine may be legally supplied after registration while local pharmacy stock is still arriving. Contact a pharmacy directly to ask whether it can dispense the tablet and whether it needs to order a particular strength.
The TGA records 3 November 2026 as the tablet’s registration date. Its decision summary was published on 11 November and says the regulator accepted evidence supporting the tablet’s safety and effectiveness for its approved uses. This is the important regulatory change behind the current availability update, rather than an announcement that the medicine is available without a prescription.
Who can be prescribed Wegovy tablets?
The TGA approved the tablets for adults as an addition to a reduced-energy diet and increased physical activity for chronic weight management. The registration also includes reducing the risk of major cardiovascular events in certain adults with established cardiovascular disease. The precise eligibility criteria depend on the approved product information and a clinician’s assessment; TGA registration does not mean every person seeking weight loss is eligible.
Wegovy tablets remain a prescription medicine. A doctor or other authorised prescriber must decide whether treatment is appropriate, considering a person’s health, other medicines and treatment goals. Do not take another semaglutide product or a different GLP-1 medicine alongside Wegovy unless a prescriber specifically directs you to. The TGA says concomitant use with other semaglutide products or other GLP-1 receptor agonists is not recommended.
How is the tablet taken?
Despite being oral, the registered Wegovy tablet has specific administration requirements. The Australian product information says to take one tablet once daily on an empty stomach after at least eight hours of fasting, swallow it whole with up to 120 mL of water, and wait at least 30 minutes before eating, drinking or taking other oral medicines. Do not split, crush or chew the tablet. Follow the directions supplied with the prescription and ask a pharmacist if the routine is unclear. The Australian product information contains the full instructions and safety details.
Does TGA registration mean PBS coverage?
No. TGA registration authorises supply for the approved indications; it does not automatically add a medicine to the PBS. The registration announcement does not establish a PBS subsidy for the Wegovy tablet. Before starting treatment, ask the prescriber or pharmacist about the current private price, whether a particular strength is in stock and any out-of-pocket costs. These details can differ by pharmacy and may change as supply develops.
What should patients expect next?
The near-term practical issue is access: whether pharmacies have received stock and can fill prescriptions promptly. Australian reporting on the 20 November launch indicates availability is beginning, but stock may not yet be uniform. Ask the pharmacist about availability before making a trip, and do not assume a reported price or launch date guarantees a particular product is on a local shelf.
A second oral GLP-1 medicine, Foundayo (orforglipron), also entered Australia’s ARTG in November, according to the TGA’s register. Its registration is a separate development; patients should rely on its own product information and supply updates rather than assume it has the same dosing, eligibility, availability or effects as Wegovy. For now, the confirmed change for Wegovy is that Australia has a registered oral version with approved adult indications and a reported start to private-prescription supply.
Frequently asked questions
Can I buy Wegovy tablets over the counter in Australia?
No. Wegovy tablets are prescription-only and require assessment by an authorised prescriber.
Which Wegovy tablet strengths are registered?
The TGA lists 1.5 mg, 4 mg, 9 mg and 25 mg strengths.
Is the Wegovy pill subsidised by the PBS?
TGA registration does not automatically provide PBS coverage. Check current subsidy and cost information with your prescriber or pharmacist.